Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases Jie YingMiaomiao ZhangYu Lu Review Article 15 February 2018 Pages: 797 - 808
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis Kazuki TakasakiMorikazu MiyamotoKenichi Furuya Original Article 02 March 2018 Pages: 809 - 814
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Suguru YamadaTsutomu FujiiYasuhiro Kodera Original Article 03 March 2018 Pages: 815 - 821
Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab Motoo NomuraAtsushi OtsukaManabu Muto Original Article 03 March 2018 Pages: 823 - 827
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial Yoshinori MunemotoMitsuro KandaHideyuki Mishima Original Article 05 March 2018 Pages: 829 - 838
Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients Keiji KurataKimikazu YakushijinHironobu Minami Original Article 06 March 2018 Pages: 839 - 846
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin David KudlowitzAlejandro VelasteguiFranco Muggia Original Article 07 March 2018 Pages: 847 - 851
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib Mengyan DengLinna LiWenbao Li Original Article 12 March 2018 Pages: 853 - 862
Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1 Peng YinGuizhen SongZhenhua Jiang Original Article 14 March 2018 Pages: 863 - 872
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK Emma DeanUdai BanerjiPeter Lawrence Original Article Open access 14 March 2018 Pages: 873 - 883
Sodium selenite attenuates lung adenocarcinoma progression by repressing SOX2-mediated stemness Weiwei ChenJiajia AnJing Du Original Article 15 March 2018 Pages: 885 - 895
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors Sherwin K. B. SyYen Lin ChiaMichael A. Eldon Original Article Open access 21 March 2018 Pages: 897 - 909
Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids Daphne L. van der VeldenGeert A. CirkelEmile E. Voest Original Article 24 March 2018 Pages: 911 - 921
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes Kosei KimuraMitsuhiko IwamotoKazuhisa Uchiyama Original Article 28 March 2018 Pages: 923 - 933
MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B Fang XiaoYueran LiMin Xue Original Article 28 March 2018 Pages: 935 - 947
Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study Ryusei MatsuyamaDaisuke MoriokaItaru Endo Original Article 28 March 2018 Pages: 949 - 955
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma Anthony B. El-KhoueiryRobert O’DonnellDavid R. Gandara Clinical Trial Report 08 March 2018 Pages: 957 - 963
EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib Thomas HuangBrigitte J. EngelmannJohn L. Villano Short Communication 02 April 2018 Pages: 965 - 968